Breast Cancer Drugs Need Survival Benefit for Full Approval, Cmtte. Says

Time to progression is a sufficiently reliable surrogate endpoint for accelerated approval of drug therapies for breast cancer, but not for unqualified regular approval of first-line therapies, FDA's Oncologic Drugs Advisory Committee decided unanimously June 7.